L-Leucine, N-((1,1-dimethylethoxy)carbonyl)- → 6-(2-Methyl-propane-1-sulfonyl)-pyridine-2-carboxylic acid [(S)-3-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-butyl]-amide

HRID 632406Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 632406
[CH2:1]([S:5]([C:8]1[N:13]=[C:12]([C:14]([OH:16])=O)[CH:11]=[CH:10][CH:9]=1)(=[O:7])=[O:6])[CH:2]([CH3:4])[CH3:3].Cl.[CH3:18][C:19]1[O:23][N:22]=[C:21]([C@H:24]([CH2:26][CH:27]([CH3:29])[CH3:28])[NH2:25])[N:20]=1.C(OC(N[C@@H](CC(C)C)C(O)=O)=O)(C)(C)C>>[CH3:28][CH:27]([CH3:29])[CH2:26][C@H:24]([NH:25][C:14]([C:12]1[CH:11]=[CH:10][CH:9]=[C:8]([S:5]([CH2:1][CH:2]([CH3:3])[CH3:4])(=[O:6])=[O:7])[N:13]=1)=[O:16])[C:21]1[N:20]=[C:19]([CH3:18])[O:23][N:22]=1

Komponenten

4

Versuchsvorschrift

The title compound was synthesized in analogy to Example 1, using 6-(isobutylsulfonyl)picolinic acid (Example 330 b) and (S)-5-methyl-α-(2-methylpropyl)-1,2,4-oxadiazole-3-methanamine hydrochloride (which was prepared from (2S)-2-[(tert-butoxycarbonyl)amino]-4-methylpentanoic acid (CAN 13139-15-6) in analogy to the procedures described in Example 38 a to e) as starting materials. MS (EI): m/e=395.2 [M+H]+.

Quellen und Nachweise

ORD-Eintrag
ord-a88987bea9e24967ba391ce5fad2d08a
Quelldatensatz
uspto-grants-2016_04
Patentnummer
US09321727B2

Notizen zur Reaktion

Wird geladen…